



OPEN

Dynamic 2-deoxy-2[18F] fluoro-D-glucose PET/MRI in human renal allotransplant patients undergoing acute kidney injury

Sahra Pajenda¹✉, Sazan Rasul², Marcus Hacker², Ludwig Wagner¹ & Barbara Katharina Geist²

Patients after solid organ kidney transplantation (KTX) often suffer from acute kidney injury (AKI). Parameters as serum creatinine indicate a loss of kidney function, although no distinction of the cause and prognosis can be made. Imaging tools measuring kidney function have not been widely in clinical use. In this observational study we evaluated 2-deoxy-2[18F] fluoro-D-glucose (FDG) PET/MRI in thirteen patients after KTX with AKI as a functional assessment of the graft. Twenty-four healthy volunteers served as control. General kidney performance (GKP), initial flow (IF) and renal response function (RF) were calculated by standardized uptake values (SUV) and time activity curves (TAC). The GKP measured for the total kidney and medulla was significantly higher in healthy patients compared to patients after KTX ($p = 0.0002$ and $p = 0.0004$, respectively), but no difference was found for the GKP of the cortex ($p = 0.59$). The IF in KTX patients correlated with renal recovery, defined as change in serum creatinine 10 days after PET/MRI ($r = 0.80$, $p = 0.001$). With regard to the RF, a negative correlation for tubular damage was found ($r = -0.74$, $p = 0.004$). In conclusion, parameters obtained from FDG PET/MRI showed a possible predictive feature for renal recovery in KTX patients undergoing AKI.

Within the first year after kidney transplantation (KTX) postoperative monitoring and care is crucial for patients' outcome. Delayed graft function (DGF) and early rejection representing a subtype of acute kidney injury (AKI) are common and make up for 20–40% of cases^{1–4}. The most susceptible site to injury by oxygen and energy deprivation is the epithelia of the proximal tubule⁵. Tubular cell injury is inflicted by hours of cold ischemia time during transportation from donor to recipient site^{6,7}. Among other potential factors for kidney dysfunction⁸ is the kidney donor profile index (KDPI)⁹ which most likely influences the organ-specific regenerative potential^{10–12}. Furthermore acceptance of expanded criteria donor (ECD) and donation after circulatory death (DCD) with prolonged warm ischemia time have led to increasing incidence of DGF^{13–15}. Potential nephrotoxic medication as calcineurin inhibitors required after kidney transplantation is an additional risk factor for acute kidney injury¹⁶.

Renal tubular cells are capable of replicating and can repopulate injured regions. This reflects the organ specific regenerative potential and is variable from individual to individual^{17–19}. Therefore renal recovery following transplantation or kidney injury due to acute events differs markedly and no reliable parameters are available in predicting the time span of allograft function regain^{20,21}.

In case of kidney function deterioration, a core needle biopsy is inevitable to confirm the diagnosis and determine the further course. One essential focus is the establishment of diagnostic tools to identify the underlying cause of renal dysfunction and the determination of predictive markers for the restoration of renal function. Various biomarkers have been tested for their diagnostic value for partial or full organ recovery following AKI in transplant recipients^{22–25}. Markers such as KIM-1, IGFBP7, TIMP-2 and other have shown promising results in predicting delayed graft function prior to known laboratory tests²⁶. However, too many factors and pathophysiological states represent the underlying causes of AKI that not one single biomarker in blood or urine could provide sufficient information for the clinician in directing the care procedures^{27–30}.

¹Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna. Waehringer Guertel 18-20, 1090, Vienna, Austria. ²Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna. Waehringer Guertel 18-20, 1090, Vienna, Austria. ✉e-mail: sahra.pajenda@meduniwien.ac.at

Non-invasive radio imaging such as sonography is a further important surveillance tool in allograft assessment^{31,32}. Although most of the imaging methods are easily accessible only estimates can be provided in respect to graft structure and perfusion, but not on complex renal function^{33–35}. Computed tomography (CT) on one side provides higher resolution but on the other side radio contrast should be better avoided in the early stages of transplantation^{31,36}. Despite all this, core needle biopsy still remains the gold standard in detecting the reason of malfunction.

In the past decade novel technology has provided additional imaging tools by combining positron emission tomography (PET) with CT or magnetic resonance imaging (MRI) using the glucose analogue radio tracer 2-deoxy-2-[18F] fluoro-D-glucose (FDG)³⁷. PET/MRI scans give information on both, accurate organ substructures and functional components³⁸. Additionally, with dynamic scans the behavior of the tracer can be observed in the kidneys, undergoing several renal processes such as filtration, re-absorption and excretion³⁹.

In this observational study, we analyzed the functional behavior of the glucose analogue FDG by the use of novel PET/MRI technology in patients after kidney transplantation with AKI. Kidney functional parameters were compared with those from healthy volunteers, which were acquired in a previous study^{40,41}. Using the MRI sequences to determine the localization of the renal cortex and medulla combined with the dynamic PET images, information on regional cellular functionality was obtained.

In parallel, we followed the function of the excretory kidney with parameters such as serum creatinine and additionally compared the PET/MRI results with renal biopsies taken close to the time of examination.

Methods

The study was carried out at the Division of Nephrology and Dialysis in Collaboration with the Division of Nuclear Medicine at the Medical University of Vienna between 2016 and 2019. Thirteen kidney recipients admitted to hospital due to DGF or kidney function deterioration were enrolled in the study. Demographic data and routine parameters were extracted from the data base of the General Hospital of Vienna. Inclusion criteria were age above 18 years, kidney transplantation regardless the immunological risk constellation, suitable to undergo PET/MRI. Exclusion criteria were claustrophobia, existing metal prosthesis and implantation of any metal devices.

All patients were monitored for their renal function by routine blood and urine testing and gave written and oral consent. The study was approved by the Local Ethics Committee of the Medical University of Vienna (protocol: 1043/2016). The study was conducted in accordance to the Declaration of Helsinki and relevant guidelines and regulations and no organs/ tissues were procured from prisoners.

Kidney biopsy. Tissues from fine needle biopsies were immediately fixed by Formalin and embedded in paraffin. Histological processing and diagnosis was performed at the Department of Pathology at the Medical University of Vienna according to the BANFF classification. Additional immunohistological staining was carried out for presence of C4d for evaluating antibody mediated rejection (ABMR).

Recovery determination. On a daily base, blood samples were drawn from all patients before and after PET/MRI examinations, from which serum creatinine was determined and eGFR was calculated according to CKD-EPI formula⁴².

A positive recovery was defined when serum creatinine decreased by >10% ten days after the PET/MRI examination, a negative recovery when serum creatinine increased by >10% ten days after the PET/MRI examination and an unchanged status was classified when the change was between $\pm 10\%$.

PET/MRI examination protocol. Directly before scan start, around 3 MBq/kg body weight FDG (isotope: fluoride-18, half-life: 109.7 min) were injected. The PET/MRI (Siemens Biograph mMR, Siemens Healthcare Diagnostics GmbH, Germany) acquisition started immediately after tracer injection and continued for 24 minutes, PET data sets were reconstructed (Siemens e7 tools) into a dynamic sequence of 60×5 s, 19×60 s a $172 \times 172 \times 127$ matrix using the ordinary Poisson ordered subset expectation maximization (OP-OSEM) 3D algorithm (3 iterations, 21 subsets, Gaussian filter). Scatter correction along with Dixon based MR-attenuation correction was performed. The MR imaging protocol consisted of a T1 weighted MRI sequence (axial breath holding and fat suppression, vibe spair).

Image data analysis. The MRI images were used to delineate volumes-of-interest (VOIs): (1) aorta descends (below the arteria renalis), drawn by hand in several layers (2) left kidney, (3) right kidney, (4) left kidney cortex (5) right kidney cortex, (6) left kidney medulla and (7) right kidney medulla. VOIs (2–3) were carefully drawn by hand in each layer; all other VOIs were delineated randomly in about 30% of all layers by a threshold VOI selection tool. After image fusion, the FDG concentrations in the according VOIs were measured in units of standardized uptake values (SUV); the time activity curves (TACs), reflecting the tracer concentration over time, were exported for further analysis. In Fig. 1, a fused PET/MRI image of a typical transplant kidney with the corresponding TACs of transplant and healthy control kidneys are presented. FDG TAC analysis was performed using an in-house Java-based tool (programmed with openjdk version 1.8.0_162), for which the aorta input function (AIF) along with the TACs were used as inputs. TACs were smoothed with a Bezier filter and the AIF was fitted with a tri-exponential function starting from its peak.

Renal function parameters from dynamic scans. To evaluate renal processes, the initial flow (IF) was determined, which is a measure used to assess the renal blood flow. IF is acquired by dividing the maximum measured tracer concentration by the total collected tracer amount in the kidney within the first 60 seconds and can be used to assess the effective renal plasma flow⁴⁰. Additionally, the renal response function (RF) was calculated in order to obtain the collected net tracer concentration over the first minute. The calculation was




Figure 1. Fused positron emission tomography and magnet resonance image (PET/MRI). **(a)** A delineated volume of interest (VOI) of the total kidneys is schematically indicated in blue. **(b)** FDG time activity curves in units of standardized uptake value (SUV). The curves show the average over all 13 measured transplant kidneys (bold blue line) \pm one standard deviation (thin blue lines), and for comparison the average over 48 healthy kidneys (bold purple line) \pm one standard deviation (thin purple lines). The general kidney performance (GKP) represents the FDG uptake between minute 2 and 3.

performed via a deconvolutional analysis as commonly applied on renogram curves from renal scintigraphies. The AIF and the total kidney TAC, from which a response function is obtained, reflect the net tracer concentration in the kidneys^{43,44}.

Furthermore, the total renal tracer uptake within the second and third minute of tracer injection was used to quantify the general kidney performance (GKP), see also Fig. 1. The uptake during this interval is commonly used to determine various kidney parameters from renal scintigraphies, e.g. glomerular filtration, renal plasma flow or renal split function^{45–47}. Recently, it has been published that this parameter is also affected after sodium-glucose linked transporter-2 inhibitor therapy in patients with type 2 diabetes mellitus⁴⁸.

Statistical analysis. Statistical analysis was performed with Gnumeric (open source software, version 1.12.20) and LibreOffice Calculator (open source software, version 4.3.7.2). Correlations were calculated with Pearson's correlation coefficient r , from which a corresponding p value was derived. The significance of the differences between groups, as well as between healthy and transplant kidneys was assessed by the student's t test with $p < 0.05$ considered as a statistically significant difference.

Results

A total of 13 renal transplant recipients were recruited and followed for a minimum of 6 weeks after the PET/MRI scan. Baseline characteristics, underlying renal disease and comorbidities are summarized in Table 1. Eight out of 13 patients were male (61.5%) and the mean age of patients was 57.9 ± 16.4 years.

With regard to kidney transplantation, information on the sex and age of the graft, data on immunological risk and mismatch are listed in Table 2. Nine patients were enrolled within the first 90 days after transplantation and measured by PET/MRI. The corresponding serum creatinine levels at the time of PET/MRI are shown in Table 2. Twelve patients have had a kidney biopsy before or after the PET/MRI was performed. In one patient no recent biopsy was available. Reasons for kidney biopsies were delayed graft function in 6 cases. A summary on the renal histology is presented in Table 2.

Recovery. Ten patients had an $eGFR < 30$ ml/min/1.73 m² at the day of the PET/MRI examination, 3 patients presented with an $eGFR > 30$ ml/min/1.73 m². Patients were treated for DGF, rejection and AKI, accordingly. Six patients showed a positive recovery, i.e. the serum creatinine decreased by $> 10\%$ (average: -36% , from 5.1 mg/dl to 3.1 mg/dl) ten days after PET/MRI examination; 4 patients had a negative recovery, i.e. an increased serum

ID	Age	Sex	BMI	Bsl sCr [mg/dl]	Underlying renal disease	Comorbidities
1	70	f	23.88	2.8–3.5	Recurrent pyelonephritis	DM II, aortic sclerosis
2	50	m	24.73	2.1–2.8	Refluxnephropathy	HTN, CABG, St.p. Hepatitis C
3	62	f	23.72	2–2.5	Chronic Interstitial nephritis	HIV, St.p. Hepatitis B + E, St.p. thyroid cancer
4	77	m	27.78	2–2.5	Cystic kidney disease	Diverticulosis, sigma adenoma
5	22	m	26.59	2–2.5	Congenital hydronephrosis	HTN, neurogenic bladder
6	58	f	13.98	1.3–3.0	Unknown	Anorexia, chronic pancreatitis, PTX + AutoTX
7	56	m	23.88	3.2–3.5	ADPKD	HTN, liver cysts
8	73	f	38.67	2.5–3	Goodpasture Syndrom	HTN, St.p. PE, adipositas, cholelithiasis
9	24	f	25.22	2.5–3	atypical HUS	HTN, St.p. CPR
10	69	f	21.88	0.8–1.2	ADPKD	HTN, Sigma diverticulosis
11	61	m	21.18	2.4–3	ADPKD	COPD, cerebellum stroke
12	66	m	31.02	3–4.0	hepatorenal syndrome	HTN, DM II, LTX, AFIB, adipositas
13	64	m	24.86	3–3.5	FSGS	HTN, DVT, adeno carcinoma of abdomen

Table 1. Baseline characteristics of the 13 included patients. Bsl sCr, baseline serum creatinine; ADPKD, autosomal dominant polycystic kidney disease; HUS, hemolytic uremic syndrome; FSGS, focal segmental glomerulosclerosis; DM II, diabetes mellitus type 2; HTN, hypertension; CABG, coronary artery bypass graft; PTX, pancreas transplantation; TX, transplantation; PE, pulmonary embolism; CPR, cardiopulmonary resuscitation; COPD, chronic obstructive pulmonary disease; LTX, liver transplantation; AFIB, atrial fibrillation; DVT, deep venous thrombosis.

ID	Sex kidney	Age kidney	Immunological risk	Mismatch	PET/MRI post TX in days	sCr [mg/dl] PET/MRI	reasons for BX	BX histology
1	f	74	normal	0–1–1	262	4,91	AKI	IFTA
2	f	64	high (DSA+, Luminex+)	1–0–0	10	5,78	DGF	ABMR, tubular injury
3	f	64	high (DSA+, Luminex+)	1–2–1	18	4,75	DGF	no rejection, TMA
4	m	79	normal	0–2–0	6	8,50	DGF	BANFF IIB
5	f	57	normal	1–1–1	12	1,94	AKI	no rejection
6	m	61	normal	2–2–1	89	1,98	AKI	no rejection
7	m	57	normal	1–1–2	66	3,64	DGF	ischemic tubular injury
8	f	73	high (DSA+, Luminex+)	2–1–2	1734	2,82	na	na
9	m	40	normal	1–2–1	42	2	DGF	no rejection, tubular injury
10	f	60	normal	0–0–0	11	1,07	AKI	no rejection
11	f	60	normal	0–1–1	21	5,14	DGF	no rejection, tubular injury
12	m	65	normal	na	1471	3,03	AKI	glomerulopathy
13	na	na	normal	1–1–0	34904	7	AKI	arteriosclerosis, IFTA

Table 2. Information on kidney transplantation, time frame of PET/MRI and biopsy. TX, transplantation; sCr, serum creatinine; DSA, donor specific antibody; BX, biopsy; DGF, delayed graft function; AKI, acute kidney injury; TMA, thrombotic microangiopathy; IFTA, interstitial fibrosis and tubular atrophy; ABMR, antibody mediated rejection; na, not available.

creatinine by in average 55% (from 2.0 mg/dl to 3.4 mg/dl); 3 patients showed no or minimal changes between \pm 10% (average: -5%, from 3.9 mg/dl to 3.7 mg/dl) in serum creatinine.

GKP general kidney performance. As depicted in Fig. 1a a VOI was drawn around the kidney after fusion of PET and MRI for calculating the distribution of FDG over time. The mean GKP of the kidney allografts and the healthy kidneys are shown in Fig. 1b. Comparing the GKP in transplanted and healthy kidneys, higher GKP was observed in healthy controls (4.5 ± 1.2 versus 5.6 ± 0.8 , respectively), which was significant for the entire kidney




Figure 2. Response function (RF) according to tubular injury. **(a)** Negative correlation between RF and tubular injury ($r = -0.83$, $p = 0.004$). **(b)** high RF was associated with mild tubular injury and low RF with severe tubular injury ($p = 0.01$).

($p = 0.0002$) and the medulla ($p = 0.0004$), but no difference was found between the GKP of the cortex ($p = 0.59$). A difference between the total GKP in patients with low tubular damage (0 to 2) and patients with high tubular damage (3–5) of 22% was found, but this did not reach significance (4.1 versus 3.3, $p = 0.17$). Also in medulla GKP a non-significant difference of 29% (4.8 versus 3.6, $p = 0.07$) was seen.

IF initial flow. The initial flow showed a strong correlation with the change in serum creatinine 10 days after the PET/MRI ($r = 0.80$, $p = 0.001$). The averaged IF was lower in patients with positive recovery and stable kidney function (1.5 min^{-1}) and higher in patients with negative recovery (1.7 min^{-1}), but this difference was not statistically significant ($p = 0.051$).

RF response function. As described earlier the renal response function (RF) indicates the net amount of FDG within the first minute. The average RF in healthy kidneys did not differ from the average RF in patients after kidney transplantation ($p = 0.9$). However, patients with severe tubular damage had lower RF ($p = 0.0004$) whereas patients with no or only mild tubular damage had a significantly higher RF ($p < 0.0001$).

Upon closer examination, a negative correlation between RF and tubular damage was found within the transplant cohort ($r = -0.74$, $p = 0.004$) (Fig. 2a). Transplanted kidneys with a higher degree of tubular damage showed lower RF compared to no or only slight tubular damage according to renal histology ($p = 0.006$) (Fig. 2b).

With regard to the prognosis of renal recovery 10 days after PET/MRI, a lower RF was associated with a decrease in serum creatinine, but was not significant (2.7 versus 4.3, $p = 0.07$). Regarding GKP, IF and RF, no influence of the donor's age, sex or time point of transplantation could be found.

Discussion

In this prospective observational study 13 patients after KTX with kidney injury underwent radio imaging based on a PET using 2-deoxy-2-[18F] fluoro-D-glucose combined with 3-Tesla MRI. Accordingly, a kinetic model based on the tracer distribution was assessed and high quality morphology on the kidney was used for anatomical allocation. This data was then compared to 24 healthy subjects undergoing the same PET/MRI imaging protocol.

One major finding was a significantly higher GKP in healthy subjects compared to the transplant patients. Interestingly, the medulla and total kidney GKP were significantly higher, whilst the purely cortical GKP showed no difference between the cohorts. This finding indicates that FDG as a glucose analogue is less accumulated in the proximal tubule or even glomeruli, which is also supported by the fact that RF, a parameter which can be understood as measure of the blood entering the kidneys within the first minute, was also higher in patients with a positive recovery. Novel data has previously demonstrated that the Henle's loop and the capillary system are involved in AKI and its potential recovery, which is supporting our present findings^{49–51}.

When looked at the initial flow, a predictive value for serum creatinine development within 10 days after PET/MRI could be seen. Additionally, RF seems of high relevance when classifying tubular damage, as significantly higher RF values were observed in patients with no or mild tubular damage. Although also medulla and total kidney GKP were higher in patients with mild tubular damage, these results were not significant.

In the early phase of kidney transplantation many risk factors due to graft characteristic, warm and cold ischemia time and immunological risk can lead to delayed graft function as a subtype of acute kidney injury. Until now, clinical decisions are based on standard care procedures including close laboratory screening, adequate immunosuppression, avoidance of nephrotoxic medication and maintaining optimal fluid balance^{52,53}. However, no commercially accessible tools are available for prediction of DGF and subsequently no estimation on prognosis can be made. In recent years biomarker-guided diagnostic approaches for renal impairment have gained importance. In respect of KTX patients, well investigated markers such as IL-18, NGAL, IGFBP7 and TIMP-2 have shown an association with DGF and worse transplant outcome^{54,55}.

Non-invasive radio imaging of renal allograft allows assessment of morphology, perfusion and urologic abnormalities. However, few data regarding functional measurements exist and are yet not implicated in clinical routine. The gold standard for diagnosis of glomerulopathies, tubular damage, interstitial fibrosis and allograft rejection remains the histopathology.

A study performing T1 mapping with MRI in patients early after kidney and lung transplantation showed that the renal cortical relaxation time is longer in patients after kidney transplantation compared to healthy controls⁵⁶.

One study has shown a predictive value for allograft dysfunction and fibrosis using a multiparametric 1.5 Tesla magnetic resonance imaging with specific diffusion weighted- imaging and T1 sequences⁵⁷. Another study using functional MRI to assess interstitial fibrosis by arterial spin labeling and apparent diffusion coefficient was able to discriminate between <50% and >50% fibrosis accordingly to histopathology⁵⁸. Clinical trials for ultrasound and MRI have attempted to diagnose acute rejection, but have not been able to discriminate accurately between different pathologies. Imaging protocols with e.g. specific nano-sized particles as contrast agents to identify immune cells as macrophages and T cells have been established, but yet are in experimental stages and only been investigated in murine models⁵⁹.

In a recently published paper the use of FDG PET combined with CT in kidney transplant recipients managed to distinguish between stable graft function and the diagnosis of subclinical rejection in the early phase of transplantation. The level of inflammation proved in allograft biopsies seemed to correlate with the FDG uptake and together with the urinary expression of chemokine CXCL9 and urine creatinine a high negative predictive value on subclinical rejection could be demonstrated. However, these results need to be confirmed in further clinical studies⁶⁰.

To date, no kinetic model in order to evaluate subunits of the kidney and the capillary system has been verified. Therefore, we tried a novel approach based on FDG PET and MRI to not only look at the morphology but shed light to a functional aspect of allograft kidneys.

In the present study we found a potential non- invasive diagnostic tool for prediction of kidney repair according to GKP, IF and RF measured by FDG PET/MRI. The repair mechanism at the renal site, in particular at the proximal tubules requiring glucose as energy supply might be of relevance. Higher FDG uptake might translate into higher energy turnover and cellular repair mechanisms indicating regain of kidney function. However, more prospective studies are required to confirm these findings and evaluate its relevance.

Conclusion

Dynamic FDG PET/MRI parameters showed a positive correlation with serum creatinine development within 10 days in kidney transplant recipients after AKI and DGF.

Limitation. No partial volume or motion corrections have been applied on the obtained VOIs. While these effects are insignificant in total kidney VOIs⁴⁰, they are certainly not in small VOIs, mainly the aorta and the medulla, which leads to higher errors. Therefore, the RF was not calculated for the medulla or the cortex VOIs. Although even the GKP from the uncorrected medulla VOI delivered better results, total kidney VOIs might be sufficient to study GKP or RF.

Furthermore, a better parameter to determine initial renal processes would certainly be the rate constant K_1 from an applied kinetic model. The non-negligible partial volume and motion effects hamper the application of a kinetic model, thus IF was chosen as a rough estimate.

We did not compare the level of total inflammation (ti) as stated in histology with the FDG uptake due to limited number of patients bearing a ti score >1. Another limitation of this study is the small cohort size and further studies are needed to validate these results.

Data availability

Data, material and associated protocols supporting the findings of this study are available upon request from the corresponding author.

Received: 24 February 2020; Accepted: 29 April 2020;

Published online: 19 May 2020

References

- Ojo, A. O. *et al.* Delayed graft function: risk factors and implications for renal allograft survival. *Transplantation* **63**(7), 968–74 (1997).
- Lebranchu, Y. *et al.* Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. *Transplant Proc* **37**(1), 345–7 (2005).
- Yarlagadda, S. G. *et al.* Marked variation in the definition and diagnosis of delayed graft function: a systematic review. *Nephrol Dial Transplant* **23**(9), 2995–3003 (2008).
- Yarlagadda, S. G. *et al.* Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. *Nephrol Dial Transplant* **24**(3), 1039–47 (2009).
- Lerolle, N. *et al.* Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. *Intensive Care Med* **36**(3), 471–8 (2010).
- Peters-Sengers, H. *et al.* Impact of Cold Ischemia Time on Outcomes of Deceased Donor Kidney Transplantation: An Analysis of a National Registry. *Transplant Direct* **5**(5), e448 (2019).
- Zhao, H. *et al.* Ischemia-Reperfusion Injury Reduces Long Term Renal Graft Survival: Mechanism and Beyond. *EBioMedicine* **28**, 31–42 (2018).
- Hofer, J. *et al.* Pre-implant biopsy predicts outcome of single-kidney transplantation independent of clinical donor variables. *Transplantation* **97**(4), 426–32 (2014).
- Rao, P. S. *et al.* A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. *Transplantation* **88**(2), 231–6 (2009).
- Chen, L. X. *et al.* Histopathologic Findings on Implantation Renal Allograft Biopsies Correlate With Kidney Donor Profile Index and 30-Day Serum Creatinine. *Transplant Proc* **51**(3), 639–646 (2019).
- Jay, C. L. *et al.* Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys. *Transplantation* **101**(4), 867–872 (2017).
- Dahmen, M. *et al.* Validation of the Kidney Donor Profile Index (KDPI) to assess a deceased donor's kidneys' outcome in a European cohort. *Sci Rep* **9**(1), 11234 (2019).
- Siedlecki, A., Irish, W. & Brennan, D. C. Delayed graft function in the kidney transplant. *Am J Transplant* **11**(11), 2279–96 (2011).
- Zens, T. J. *et al.* The impact of kidney donor profile index on delayed graft function and transplant outcomes: A single-center analysis. *Clin Transplant* **32**(3), e13190 (2018).

15. Rege, A. *et al.* Trends in Usage and Outcomes for Expanded Criteria Donor Kidney Transplantation in the United States Characterized by Kidney Donor Profile Index. *Cureus* **8**(11), e887 (2016).
16. Krejci, K. *et al.* Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. *Transpl Int* **23**(4), 364–73 (2010).
17. Humphreys, B. D. *et al.* Intrinsic epithelial cells repair the kidney after injury. *Cell Stem Cell* **2**(3), 284–91 (2008).
18. Castrop, H. The Role of Renal Interstitial Cells in Proximal Tubular Regeneration. *Nephron* **141**(4), 265–272 (2019).
19. Knafli, D. *et al.* Urinary nephrospheres indicate recovery from acute kidney injury in renal allograft recipients - a pilot study. *BMC Nephrol* **20**(1), 251 (2019).
20. Irish, W. D. *et al.* A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. *Am J Transplant* **10**(10), 2279–86. (2010).
21. Molnar, M. Z. *et al.* Predictive Score for Posttransplantation Outcomes. *Transplantation* **101**(6), 1353–1364 (2017).
22. Bank, J. R. *et al.* Kidney injury molecule-1 staining in renal allograft biopsies 10 days after transplantation is inversely correlated with functioning proximal tubular epithelial cells. *Nephrol Dial Transplant* **32**(12), 2132–2141 (2017).
23. Koo, T. Y. *et al.* Pre-transplant Evaluation of Donor Urinary Biomarkers can Predict Reduced Graft Function After Deceased Donor Kidney Transplantation. *Medicine (Baltimore)* **95**(11), e3076 (2016).
24. Pajenda, S. *et al.* NephroCheck data compared to serum creatinine in various clinical settings. *BMC Nephrol* **16**, 206 (2015).
25. van den Akker, E. K. *et al.* Neutrophil Gelatinase-Associated Lipocalin, but Not Kidney Injury Marker 1, Correlates with Duration of Delayed Graft Function. *Eur Surg Res* **55**(4), 319–327 (2015).
26. Malyszko, J. *et al.* Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. *Sci Rep* **5**, 11684 (2015).
27. Ronco, C., Bellomo, R. & Kellum, J. A. Acute kidney injury. *Lancet* **394**(10212), 1949–1964 (2019).
28. Moriyama, T. *et al.* Comparison of three early biomarkers for acute kidney injury after cardiac surgery under cardiopulmonary bypass. *J Intensive Care* **4**, 41 (2016).
29. Deng, Y. *et al.* Evaluation of clinically available renal biomarkers in critically ill adults: a prospective multicenter observational study. *Crit Care* **21**(1), 46 (2017).
30. McIlroy, D. R. *et al.* Combining Novel Renal Injury Markers with Delta Serum Creatinine Early after Cardiac Surgery and Risk-Stratification for Serious Adverse Outcomes: An Exploratory Analysis. *J Cardiothorac Vasc Anesth* **32**(5), 2190–2200 (2018).
31. Grenier, N., Merville, P. & Combe, C. Radiologic imaging of the renal parenchyma structure and function. *Nat Rev Nephrol* **12**(6), 348–59 (2016).
32. Sugi, M. D. *et al.* Imaging of Renal Transplant Complications throughout the Life of the Allograft: Comprehensive Multimodality Review. *Radiographics* **39**(5), 1327–1355 (2019).
33. Preuss, S. *et al.* Sonography of the renal allograft: Correlation between doppler sonographic resistance index (RI) and histopathology. *Clin Hemorheol Microcirc* **70**(4), 413–422 (2018).
34. Granata, A. *et al.* Renal transplant vascular complications: the role of Doppler ultrasound. *J Ultrasound* **18**(2), 101–7 (2015).
35. Hamilton, D., Miola, U. J. & Payne, M. C. The renal transplant perfusion index: reduction in the error and variability. *Eur J Nucl Med* **21**(3), 232–8 (1994).
36. Stacul, F. *et al.* Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. *Eur Radiol* **21**(12), 2527–41 (2011).
37. Meller, J., Sahlmann, C. O. & Scheel, A. K. 18F-FDG PET and PET/CT in fever of unknown origin. *J Nucl Med* **48**(1), 35–45 (2007).
38. Derlin, T. *et al.* Integrating MRI and Chemokine Receptor CXCR4-Targeted PET for Detection of Leukocyte Infiltration in Complicated Urinary Tract Infections After Kidney Transplantation. *J Nucl Med* **58**(11), 1831–1837 (2017).
39. Sala-Rabanal, M. *et al.* Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. *J Physiol* **594**(15), 4425–38 (2016).
40. Geist, B. K. *et al.* Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects. *EJNMMI Res* **8**(1), 37 (2018).
41. Geist, B. K. *et al.* Assessment of the kidney function parameters split function, mean transit time, and outflow efficiency using dynamic FDG-PET/MRI in healthy subjects. *European Journal of Hybrid Imaging* **3**, 3 (2019).
42. Levey, A. S. *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* **150**(9), 604–12 (2009).
43. Durand, E. *et al.* International Scientific Committee of Radionuclides in Nephrourology (ISCORN) consensus on renal transit time measurements. *Semin Nucl Med* **38**(1), 82–102 (2008).
44. Kempf, V. A FORTRAN program for deconvolution analysis using the matrix algorithm method with special reference to renography. *Comput Methods Programs Biomed* **24**(2), 107–16 (1987).
45. Wesolowski, M. J. *et al.* A simple method for determining split renal function from dynamic (99m)Tc-MAG3 scintigraphic data. *Eur J Nucl Med Mol Imaging* **43**(3), 550–8 (2016).
46. Ortapamuk, H. *et al.* Differential renal function in the prediction of recovery in adult obstructed kidneys after pyeloplasty. *Ann Nucl Med* **17**(8), 663–8 (2003).
47. Gates, G. F. Glomerular filtration rate: estimation from fractional renal accumulation of 99mTc-DTPA (stannous). *AJR Am J Roentgenol* **138**(3), 565–70 (1982).
48. Rasul, S. *et al.* Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using (18)F-FDG PET/MRI. *BMJ Open Diabetes Res Care* **8**, 1 (2020).
49. Takasu, O. *et al.* Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. *Am J Respir Crit Care Med* **187**(5), 509–17 (2013).
50. Post, E. H. *et al.* Renal perfusion in sepsis: from macro- to microcirculation. *Kidney Int* **91**(1), 45–60 (2017).
51. Calzavacca, P. *et al.* Cortical and Medullary Tissue Perfusion and Oxygenation in Experimental Septic Acute Kidney Injury. *Crit Care Med* **43**(10), e431–9 (2015).
52. Calixto Fernandes, M. H. *et al.* Perioperative fluid management in kidney transplantation: a black box. *Crit Care* **22**(1), 14 (2018).
53. Salifu, M. O., Tedla, F. & Markell, M. S. Management of the well renal transplant recipient: outpatient surveillance and treatment recommendations. *Semin Dial* **18**(6), 520–8 (2005).
54. Hall, I. E. *et al.* IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. *J Am Soc Nephrol* **21**(1), 189–97 (2010).
55. Pianta, T. J. *et al.* Evaluation of biomarkers of cell cycle arrest and inflammation in prediction of dialysis or recovery after kidney transplantation. *Transpl Int* **28**(12), 1392–404 (2015).
56. Peperhove, M. *et al.* Assessment of acute kidney injury with T1 mapping MRI following solid organ transplantation. *Eur Radiol* **28**(1), 44–50 (2018).
57. Bane, O. *et al.* Multiparametric magnetic resonance imaging shows promising results to assess renal transplant dysfunction with fibrosis. *Kidney Int* **97**(2), 414–420 (2020).
58. Wang, W. *et al.* Combination of Functional Magnetic Resonance Imaging and Histopathologic Analysis to Evaluate Interstitial Fibrosis in Kidney Allografts. *Clin J Am Soc Nephrol* **14**(9), 1372–1380 (2019).
59. Jehn, U. *et al.* Renal Allograft Rejection: Noninvasive Ultrasound- and MRI-Based Diagnostics. *Contrast Media Mol Imaging* **2019**, 3568067 (2019).
60. Hanssen, O. *et al.*, Diagnostic yield of (18) F-FDG PET/CT imaging and urinary CXCL9/creatinine levels in kidney allograft subclinical rejection. *Am J Transplant*, 2019.

Author contributions

S.P.: Study design, patient recruitment, data collection and analysis, writing the manuscript. S.R.: study design, in charge of performance of PET/MRI scans. M.H.: supported the investigation as chief of the department and provided material and technology, manuscript editing L.W.: Study design, patient recruitment, manuscript editing B.K.G.: performance of PET/MRI scan and data analysis and statistics, manuscript editing.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to S.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020